A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults - Trial NCT06394167
Access comprehensive clinical trial information for NCT06394167 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Not yet recruiting. The study focuses on Pain. Target enrollment is 110 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2025
Primary Outcome
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)
 of intravenously administered VX-993 at different doses in healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06394167
Non-Device Trial